PT - JOURNAL ARTICLE AU - Erola Pairo-Castineira AU - Konrad Rawlik AU - Lucija Klaric AU - Athanasios Kousathanas AU - Anne Richmond AU - Jonathan Millar AU - Clark D Russell AU - Tomas Malinauskas AU - Ryan Thwaites AU - Alex Stuckey AU - Christopher A Odhams AU - Susan Walker AU - Fiona Griffiths AU - Wilna Oosthuyzen AU - Kirstie Morrice AU - Sean Keating AU - Alistair Nichol AU - Malcolm G Semple AU - Julian Knight AU - Manu Shankar-Hari AU - Charlotte Summers AU - Charles Hinds AU - Peter Horby AU - Lowell Ling AU - Danny McAuley AU - Hugh Montgomery AU - Peter J.M. Openshaw AU - Timothy Walsh AU - Albert Tenesa AU - GenOMICC Investigators AU - SCOURGE Consortium AU - ISARIC4C Investigators AU - 23andMe AU - Richard H Scott AU - Mark J Caulfield AU - Loukas Moutsianas AU - Chris P Ponting AU - James F Wilson AU - Veronique Vitart AU - Alexandre C Pereira AU - Andre Luchessi AU - Esteban Parra AU - Raquel Cruz-Guerrero AU - Angel Carracedo AU - Angie Fawkes AU - Lee Murphy AU - Kathy Rowan AU - Andy Law AU - Sara Clohisey Hendry AU - J. Kenneth Baillie TI - GWAS and meta-analysis identifies multiple new genetic mechanisms underlying severe Covid-19 AID - 10.1101/2022.03.07.22271833 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.07.22271833 4099 - http://medrxiv.org/content/early/2022/03/07/2022.03.07.22271833.short 4100 - http://medrxiv.org/content/early/2022/03/07/2022.03.07.22271833.full AB - Pulmonary inflammation drives critical illness in Covid-19, 1;2 creating a clinically homogeneous extreme phenotype, which we have previously shown to be highly efficient for discovery of genetic associations. 3;4 Despite the advanced stage of illness, we have found that immunomodulatory therapies have strong beneficial effects in this group. 1;5 Further genetic discoveries may identify additional therapeutic targets to modulate severe disease. 6 In this new data release from the GenOMICC (Genetics Of Mortality in Critical Care) study we include new microarray genotyping data from additional critically-ill cases in the UK and Brazil, together with cohorts of severe Covid-19 from the ISARIC4C 7 and SCOURGE 8 studies, and meta-analysis with previously-reported data. We find an additional 14 new genetic associations. Many are in potentially druggable targets, in inflammatory signalling (JAK1, PDE4A), monocyte-macrophage differentiation (CSF2), immunometabolism (SLC2A5, AK5), and host factors required for viral entry and replication (TMPRSS2, RAB2A). As with our previous work, these results provide tractable therapeutic targets for modulation of harmful host-mediated inflammation in Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome Trust Senior Research Fellowship (J.K.Baillie, 223164/Z/21/Z), the Department of Health and Social Care (DHSC), Illumina, LifeArc, the Medical Research Council, UKRI, a BBSRC Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and BBS/E/D/30002275) and UKRI grants MC_PC_20004, MC_PC_19025, MC_PC_1905, and MRNO2995X/1. This research is supported in part by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20029). We acknowledge NHS Digital, Public Health England and the Intensive Care National Audit and Research Centre who provided clinical data on the participants. This study owes a great deal to the National Institute for Healthcare Research Clinical Research Network (NIHR CRN) and the Chief Scientist Office (Scotland), who facilitate recruitment into research studies in NHS hospitals, and to the global ISARIC and InFACT consortia. GenOMICC genotype controls were obtained using UK Biobank Resource under project 788 funded by Roslin Institute Strategic Programme Grants from the BBSRC (BBS/E/D/10002070 and BBS/E/D/30002275) and Health Data Research UK (references HDR-9004 and HDR-9003)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We performed TWAS in the MetaXcan framework and the GTExv8 eQTL and sQTL MASHR-M models available for download in http://predictdb.org/. Publicly-available HGI data was downloaded from https://www.covid19hg.org/results/r6/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, including downloadable summary data and access applications for individual-level data, can be obtained through the GenOMICC gateway site https://genomicc.org/data. https://genomicc.org/data